Hyundai Bioscience Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 40.8 million compared to KRW 30 million a year ago. Net loss was KRW 2,337.26 million compared to KRW 5,882.57 million a year ago. Basic loss per share from continuing operations was KRW 59 compared to KRW 149 a year ago. Diluted loss per share from continuing operations was KRW 59 compared to KRW 149 a year ago. Basic loss per share was KRW 59 compared to KRW 149 a year ago.
For the six months, sales was KRW 84.16 million compared to KRW 60.29 million a year ago. Net loss was KRW 4,434.08 million compared to KRW 8,017 million a year ago. Basic loss per share from continuing operations was KRW 112 compared to KRW 205 a year ago. Diluted loss per share from continuing operations was KRW 112 compared to KRW 205 a year ago. Basic loss per share was KRW 112 compared to KRW 205 a year ago.